New Clinical Access Program to Expand Access to Tuberculosis Treatment Pretoria, 10 December 2020—TB Alliance welcomes the Wits Health Consortium […]
NEW YORK (October 30, 2020)—At the Prix Galien Awards Ceremony on Thursday, October 29, The Galien Foundation named pretomanid the
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
NEW YORK (October 14, 2020)—The World Health Organization’s Global Tuberculosis (TB) Report 2020 confirms that efforts to track and treat TB
PRETORIA — Today marks the one year anniversary of the US FDA’s approval of pretomanid as part of the BPaL
NEW YORK (August 4, 2020)—Fast Company today announced its 11th annual list of the Most Creative People in Business, honoring
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved
